Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The investigators want to test whether infusions of intravenous immunoglobulin - a blood
product known to modify immune responses - in early pregnancy will increase the chance of a
subsequent live birth in women with three or more miscarriages after a birth and a total of
at least four miscarriages. This will be done in a trial where 82 patients will be randomly
allocated to infusions with intravenous immunoglobulin or placebo during pregnancy.
Phase:
Phase 3
Details
Lead Sponsor:
Rigshospitalet, Denmark
Collaborator:
The Ministry of Science, Technology and Innovation, Denmark